Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist

Suneeta Tumati, Tally M. Largent-Milnes, Attila Keresztes, Jiyang Ren, William R Roeske, Todd W Vanderah, Eva V. Varga

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization. Since activation of glial CB2 cannabinoid receptors attenuates spinal glial activation in neuropathies, we hypothesized that CB2 agonists may also attenuate sustained morphine-mediated spinal glial activation and pain sensitization. Our data indicate that co-administration of a CB2-selective agonist (AM 1241) attenuates morphine (intraperitoneal; twice daily; 6. days)-mediated thermal hyperalgesia and tactile allodynia in rats. A CB2 (AM 630) but not a CB1 (AM 251) antagonist mitigated this effect. AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment.

Original languageEnglish (US)
Pages (from-to)23-31
Number of pages9
JournalJournal of Neuroimmunology
Volume244
Issue number1-2
DOIs
StatePublished - Mar 2012

Fingerprint

Cannabinoid Receptor Agonists
Hyperalgesia
Neuroglia
Morphine
Cannabinoid Receptor CB2
Therapeutics
Pain
Interleukin-1
Astrocytes

Keywords

  • Allodynia
  • CB2 agonist
  • Hyperalgesia
  • Morphine
  • Pain sensitization
  • Spinal glia

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. / Tumati, Suneeta; Largent-Milnes, Tally M.; Keresztes, Attila; Ren, Jiyang; Roeske, William R; Vanderah, Todd W; Varga, Eva V.

In: Journal of Neuroimmunology, Vol. 244, No. 1-2, 03.2012, p. 23-31.

Research output: Contribution to journalArticle

@article{a17a66831cac4ec59428331c75aa9fe9,
title = "Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist",
abstract = "Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization. Since activation of glial CB2 cannabinoid receptors attenuates spinal glial activation in neuropathies, we hypothesized that CB2 agonists may also attenuate sustained morphine-mediated spinal glial activation and pain sensitization. Our data indicate that co-administration of a CB2-selective agonist (AM 1241) attenuates morphine (intraperitoneal; twice daily; 6. days)-mediated thermal hyperalgesia and tactile allodynia in rats. A CB2 (AM 630) but not a CB1 (AM 251) antagonist mitigated this effect. AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment.",
keywords = "Allodynia, CB2 agonist, Hyperalgesia, Morphine, Pain sensitization, Spinal glia",
author = "Suneeta Tumati and Largent-Milnes, {Tally M.} and Attila Keresztes and Jiyang Ren and Roeske, {William R} and Vanderah, {Todd W} and Varga, {Eva V.}",
year = "2012",
month = "3",
doi = "10.1016/j.jneuroim.2011.12.021",
language = "English (US)",
volume = "244",
pages = "23--31",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist

AU - Tumati, Suneeta

AU - Largent-Milnes, Tally M.

AU - Keresztes, Attila

AU - Ren, Jiyang

AU - Roeske, William R

AU - Vanderah, Todd W

AU - Varga, Eva V.

PY - 2012/3

Y1 - 2012/3

N2 - Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization. Since activation of glial CB2 cannabinoid receptors attenuates spinal glial activation in neuropathies, we hypothesized that CB2 agonists may also attenuate sustained morphine-mediated spinal glial activation and pain sensitization. Our data indicate that co-administration of a CB2-selective agonist (AM 1241) attenuates morphine (intraperitoneal; twice daily; 6. days)-mediated thermal hyperalgesia and tactile allodynia in rats. A CB2 (AM 630) but not a CB1 (AM 251) antagonist mitigated this effect. AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment.

AB - Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization. Since activation of glial CB2 cannabinoid receptors attenuates spinal glial activation in neuropathies, we hypothesized that CB2 agonists may also attenuate sustained morphine-mediated spinal glial activation and pain sensitization. Our data indicate that co-administration of a CB2-selective agonist (AM 1241) attenuates morphine (intraperitoneal; twice daily; 6. days)-mediated thermal hyperalgesia and tactile allodynia in rats. A CB2 (AM 630) but not a CB1 (AM 251) antagonist mitigated this effect. AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment.

KW - Allodynia

KW - CB2 agonist

KW - Hyperalgesia

KW - Morphine

KW - Pain sensitization

KW - Spinal glia

UR - http://www.scopus.com/inward/record.url?scp=84857919068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857919068&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2011.12.021

DO - 10.1016/j.jneuroim.2011.12.021

M3 - Article

VL - 244

SP - 23

EP - 31

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -